Acurx Pharmaceuticals, Inc.
ACXP· Nasdaq
ACXPAcurx Pharmaceuticals, Inc.
Filed Aug 8, 2024 · 10-Q · 39 days after period end · 0001558370-24-011587
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$4.12M | -$3.45M | -$2.62M | -$4.00M |
| EPS Diluted | -$5.21 | -$0.28 | -$0.26 | -$0.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end
